173 related articles for article (PubMed ID: 11592536)
21. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
22. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
23. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S
J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
Cantor LB; Hoop J; Katz LJ; Flartey K;
Clin Ther; 2001 Jul; 23(7):1032-9. PubMed ID: 11519768
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
27. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
28. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT
Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568
[TBL] [Abstract][Full Text] [Related]
29. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
30. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany.
Thelen U; Buchholz P; Kimmich F
Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517
[TBL] [Abstract][Full Text] [Related]
31. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
32. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.
Evans DW; Hosking SL; Gherghel D; Bartlett JD
Br J Ophthalmol; 2003 Dec; 87(12):1463-5. PubMed ID: 14660453
[TBL] [Abstract][Full Text] [Related]
33. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Katz LJ; Simmons ST; Craven ER
Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
[TBL] [Abstract][Full Text] [Related]
35. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
36. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
37. Patient persistency with pharmacotherapy in the management of glaucoma.
Reardon G; Schwartz GF; Mozaffari E
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S44-52. PubMed ID: 12948052
[TBL] [Abstract][Full Text] [Related]
38. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
39. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.
García-Sánchez J; Rouland JF; Spiegel D; Pajic B; Cunliffe I; Traverso C; Landry J
Br J Ophthalmol; 2004 Jul; 88(7):877-83. PubMed ID: 15205229
[TBL] [Abstract][Full Text] [Related]
40. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
